LAG3 and neoplasm: In early-stage breast cancer, high co-expression of TIGIT and other immune checkpoint receptors—including PD-1, CTLA-4, LAG-3, and TIM-3—on tumor-infiltrating lymphocytes correlates with increased disease aggressiveness (54).